Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has received approval from the FDA of its abbreviated new drug application for Potassium-Chloride extended-release capsules USP in the 8mEq and 10mEq strengths.
Subscribe to our email newsletter
Potassium-Chloride is the generic equivalent to KV Pharmaceutical’s Micro-K Extencaps USP and is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis.
Watson plans to launch its Potassium Chloride extended-release product during the third quarter of 2008. The specific launch date will depend upon the timing of product validation activities and manufacturing of launch.